Skip to main content
. Author manuscript; available in PMC: 2019 May 15.
Published in final edited form as: Bioorg Med Chem. 2018 Apr 6;26(9):2514–2529. doi: 10.1016/j.bmc.2018.04.016

Fig. 9.

Fig. 9

Selectivity data of antagonists in PAR1 (TFLLRN-NH2)- and PAR2 (SLIGKV-NH2)-driven iCa2+ mobilizationa aML161, RR90, Q94, TJF5 (Fairlie’s PAR2 antagonist) were used at 10 μM; Vorapaxar, Atopaxar, and RWJ-58259 were at 0.316 μM. TFLLRN-NH2 and SLIGKV-NH2 were used at 3.16 μM; Vehicle (V) = 10% DMSO-HBSS/HEPES.